

# ESMO Preceptorship on NSCLC and SCLC

## PROGRAMME

## ESMO PRECEPTORSHIP

**SINGAPORE  
8-9 DECEMBER 2025**

### CO-CHAIRS

---

Tony S. K. Mok, Hong Kong SAR, China

---

Solange Peters, Switzerland

---

[esmo.org](https://esmo.org)

# ESMO PRECEPTORSHIP PROGRAMME

## NSCLC and SCLC

New standards of care and future perspectives

**Singapore**  
**8-9 December 2025**

---

**CO-CHAIRS** Tony S. K. Mok, Hong Kong SAR, China  
Solange Peters, Switzerland

**SPEAKERS** Thanyanan Baisamut, Thailand  
Lizza Hendriks, Netherlands  
Hidehito Horinouchi, Japan  
David Planchard, France  
Sanjay Popat, United Kingdom  
Noemi Reguart, Spain  
Jordi Remon Masip, France  
Pan-Chyr Yang, Taiwan

---

## LEARNING OBJECTIVES

- To learn about best clinical practice in the management of NSCLC in early, locally advanced and metastatic stages
- To learn about the management of patients with actionable driver alterations and novel targeted agents for advanced NSCLC
- To understand the role of immune checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about the systemic treatment of SCLC and pleural mesothelioma

---

## ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

## ACKNOWLEDGEMENTS

This educational programme has been supported by:

**AMGEN**<sup>®</sup>



---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4, 6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Monday, 8 December 2025

09:00-09:10 10'	Welcome and introduction	Tony S. K. Mok, HK SAR, CN Solange Peters, CH
09:10-10:00 50'	<b>SESSION 1</b> Screening	Chair: Solange Peters, CH
20'	Screening in Asia	Pan-Chyr Yang, TW
20'	Screening: The smoker-based picture	Lizza Hendriks, NL
10'	Q&A	All
10:00-10:30	<b>Coffee break</b>	
10:30-11:50 80'	<b>SESSION 2</b> Advances in the treatment of early-stage lung cancer	Chair: Tony S. K. Mok, HK SAR, CN
25'	Perioperative I/O	Solange Peters, CH
20'	Perioperative TKIs	Hidehito Horinouchi, JP
20'	The treatment paradigm for unresectable stage III NSCLC	Lizza Hendriks, NL
15'	Q&A	All
11:50-12:45 55'	<b>SESSION 3</b> Advanced-stage lung cancer	Chair: Tony S. K. Mok, HK SAR, CN
20'	State-of-the-art in immunotherapy for advanced-stage disease	Noemi Reguart, ES
20'	Addressing resistance with immunotherapy	Solange Peters, CH
15'	Q&A	All
12:45-13:45	<b>Lunch</b>	
13:45-15:10 85'	<b>SESSION 4</b> Hitting the target – Part I	Chair: Solange Peters, CH
25'	Optimal approach for ADC in NSCLC	David Planchard, FR
20'	What is new about EGFR mutations	Tony S. K. Mok, HK SAR, CN
25'	What about fusions?	Jordi Remon Masip, FR
15'	Q&A	All
15:10-15:40	<b>Coffee break</b>	
15:40-16:35 55'	<b>SESSION 5</b> Hitting the target – Part II	Chair: Tony S. K. Mok, HK SAR, CN
25'	Additional actionable mutations	Thanyanan Baisamut, TH
20'	Can we conquer KRAS mutations?	Tony S. K. Mok, HK SAR, CN
10'	Q&A	All
16:35-17:50 75'	<b>SESSION 6</b> Participants clinical case discussion	Chair: Solange Peters, CH
75'	Participants clinical case discussion (5x15') NSCLC x 2 cases / SCLC x 3 cases	Faculty
18:00	<b>Networking cocktail</b>	

## Tuesday, 9 December 2025

<b>09:00-10:30</b> 90'	<b>SESSION 7</b> Novel approach to SCLC – Part I	<b>Chair:</b> Tony S. K. Mok, HK SAR, CN
25'	Standard of care management of limited-stage SCLC	David Planchard, FR
25'	Frontline standard of care management of extensive-stage SCLC (excluding TCE and ADCs)	Noemi Reguart, ES
25'	Second-line strategies for extensive-stage SCLC (excluding TCE and ADCs)	Thanyanan Baisamut, TH
15'	Q&A	All
<b>10:30-11:00</b>	<b>Coffee break</b>	
<b>11:00-12:30</b> 90'	<b>SESSION 8</b> Novel approach to SCLC – Part II	<b>Chair:</b> Solange Peters, CH
25'	T-cell engagers for SCLC	Sanjay Popat, UK
25'	Perspectives in drug development in SCLC (ADCs, bispecifics)	Hidehito Horinouchi, JP
25'	Areas of controversy in SCLC: PCI, PS2, biomarkers, treatment sequence	Jordi Remon Masip, FR
15'	Q&A	All
<b>12:30-12:40</b> 10'	<b>Conclusion and farewell</b>	<b>Tony S. K. Mok, HK SAR, CN</b> <b>Solange Peters, CH</b>
<b>12:40-13:40</b>	<b>Lunch</b>	

**Note:** Each 15-min slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / interactive panel discussion